Pathology and Tissue Core

M.D.Ancierson癌症中心白血病孢子的主要目标是改善对 白血病患者。实现这一目标的一个基本组成部分是进行有重点的 涉及人体组织和血液样本的翻译研究，允许研究人的生物学 靶组织和正常组织，靶组织和正常组织治疗效果的评价和调节 相关生物标志物。病理和组织核心将收集、处理和维护人类组织 病人的标本，并将这些组织分发给白血病孢子调查员。 病理学和组织核心有以下目标： 1.建立和维护一个完整的细胞、血清、DNA、RNA和来自血液的蛋白质的储存库 以及从接受治疗或治疗的白血病和MDS患者获得的骨髓样本 参与孢子相关研究的M.D.安德森癌症中心和其他中心的评估 临床试验。在诊断时和治疗期间/之后收集和处理样本 在缓解或复发时使用与孢子相关的临床方案。核心将分发 将组织标本交给白血病孢子调查员进行分析并提供专业知识 对白血病孢子项目中的组织切片进行的研究的解释。核心意志 提供白血病孢子样本的全面血液病理学特征 项目。 2.维护一个包含详细临床和病理数据的全面、前瞻性的交互数据库 适用于在M.D.安德森癌症中心接受护理或评估的LeukeiTiia和MDS患者 和其他参与孢子相关临床试验的中心。 3.通过共享血液促进白血病间和白血病外孢子的协作 和骨髓资源。 在过去9年的资助中，核心完成了向所有白血病提供样本的使命 孢子项目，以及外部调查人员的要求。在本供资期间(2008-2011年)，我们 已经向95个孢子研究人员和白血病患者分发了10,278瓶材料 孢子外的研究人员。 相关性(请参阅说明)： 对白血病的研究取决于从患者那里获得的白血病样本的可用性。这些 白血病细胞被用来制造DNA、RNA和蛋白质，这些DNA、RNA和蛋白质被用来识别 疾病和活细胞，用于测试白血病细胞对刺激或潜在的新的 治疗。该中心提供患者样本，这些样本是了解和治愈白血病的关键。

The priinary aim of the M.D. Ancierson Cancer Center Leukemia SPORE is to improve the treatment of patients with leukemia. A fundamental component to meeting this objective is the conduct of focused translational research involving human tissue and blood specimens, allowing investigation of the biology of target and normal tissues, evaluation of treatment effects on both target and normal tissue, and modulation of, relevant biomarkers. The Pathology and Tissue Core will collect, process, and maintain human tissue specimens from patients and m\\ distribute these tissues to the Leukemia SPORE investigators. The Pathology and Tissue Core has the following aims: 1. Develop and maintain a repository of intact cells, serum, DNA, RNA, and protein derived from blood and bone marrow specimens obtained from patients with leukemia and MDS receiving care or evaluation at M.D. Anderson Cancer Center and other centers participating in SPORE-associated clinical trials. Samples are collected and processed at the time of diagnosis and during/after therapy with SPORE-associated clinical protocols, while in remission or at relapse. The Core will distribute tissue specimens to the Leukemia SPORE investigators for analysis and provide expertise in the interpretation of studies performed on tissue sections within Leukemia SPORE projects. The Core will provide comprehensive hematopathologic characterization of the samples used in Leukemia SPORE projects. 2. Maintain a comprehensive, prospective interactive database with detailed clinical and pathologic data for patients with leukeiTiia and MDS receiving care or evaluation at M.D. Anderson Cancer Center and other centers participating in SPORE-associated clinical trials. 3. Facilitate inter-leukemia SPORE and extra-leukemia SPORE collaborations through sharing of blood and marrow resources. Over the past 9 years of funding, the Core has fulfilled its mission of providing samples to all Leukemia SPORE projects, as well as outside investigators' requests. In the current funding period (2008-2011), we have distributed 10,278 vials of material to 95 requests to SPORE researchers as well as leukemia researchers outside the SPORE. RELEVANCE (See instructions): Research into leukemia depends on the availability of leukemic samples obtained from patients. These leukemic cells are used to make DNA, RNA and protein, which are used to identify the characteristics of the disease and viable cells which are used to test how leukemic cells respond to stimulation, or potential new therapies. This Core provides the patient samples that are key to understanding and curing leukemia.